These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 9815799)

  • 41. Immunohistochemical detection of p53 protein and prognosis of surgically resected non-small-cell lung cancer.
    Quantin X; Pujol JL; Lehmann M; Simony J; Serre I; Michel FB
    Cancer Detect Prev; 1997; 21(5):418-25. PubMed ID: 9307845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Bronchial cancer--development, diagnosis, therapy, prognosis].
    Zöchbauer S; Krajnik G; Huber H
    Wien Klin Wochenschr; 1994; 106(14):431-47. PubMed ID: 7941590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic role of cyclin D1 in non small cell lung cancer: an immunohistochemical analysis.
    Caputi M; De Luca L; Papaccio G; D'Aponte A; Cavallotti I; Scala P; Scarano F; Manna M; Gualdiero L; De Luca B
    Eur J Histochem; 1997; 41(2):133-8. PubMed ID: 9271706
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers.
    Pujol JL; Simony J; Laurent JC; Richer G; Mary H; Bousquet J; Godard P; Michel FB
    Cancer Res; 1989 May; 49(10):2797-802. PubMed ID: 2540908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
    Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
    Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer.
    Ohgami A; Mitsudomi T; Sugio K; Tsuda T; Oyama T; Nishida K; Osaki T; Yasumoto K
    Ann Thorac Surg; 1997 Aug; 64(2):363-7. PubMed ID: 9262576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Evaluation of survival and prognostic factors of 2,000 broncho-pulmonary cancers registered during 10 years in a multidisciplinary oncology department].
    Moro D; Nagy-Mignotte H; Bolla M; Colonna M; Brichon PY; Brambilla C; Schaerer R; Vrousos C
    Bull Cancer; 1997 Feb; 84(2):155-61. PubMed ID: 9180838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
    Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
    Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
    Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
    Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Practical approaches to the treatment of patients with extensive stage small cell lung cancer.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):3-6. PubMed ID: 7522349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. p53 expression in non small cell lung cancer: clinical and biological correlations.
    Fontanini G; Bigini D; Vignati S; Macchiarini P; Pepe S; Angeletti CA; Pingitore R; Squartini F
    Anticancer Res; 1993; 13(3):737-42. PubMed ID: 8100413
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival of chemo-radiotherapy-treated and thermotherapy-treated patients with unresectable lung cancer.
    Rizzo S
    Oncol Rep; 1998; 5(3):667-71. PubMed ID: 9538173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
    Liu Y; Wang J; Zhang H; Fu XM; Wang HQ
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun; 33(6):427-31. PubMed ID: 20979814
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship of p53 alteration and myc family gene overexpression with the clinical characteristics of lung cancer.
    Bai L; Sun Y; Li S
    Chin Med J (Engl); 1997 Apr; 110(4):250-4. PubMed ID: 9594222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Lung cancer].
    Alexandersen O
    Tidsskr Nor Laegeforen; 2001 Feb; 121(4):407-9. PubMed ID: 11255851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage.
    David O; Jett J; LeBeau H; Dy G; Hughes J; Friedman M; Brody AR
    Clin Cancer Res; 2004 Oct; 10(20):6865-71. PubMed ID: 15501963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutant p53 product in patients with stage III cervical cancer.
    Gitsch G; Kainz C; Joura E; Breitenecker G
    Anticancer Res; 1992; 12(6B):2241-2. PubMed ID: 1295470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung.
    Komiya T; Hirashima T; Takada M; Masuda N; Yasumitsu T; Nakagawa K; Hosono Y; Kikui M; Tsuji S; Fukuoka M; Kawase I
    Anticancer Res; 1997; 17(5B):3721-4. PubMed ID: 9427768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer.
    Yang H; Wang W; Zhang Y; Zhao J; Lin E; Gao J; He J
    Clin Lung Cancer; 2011 May; 12(3):166-71. PubMed ID: 21663859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of flow and image DNA cytometry in prediction of patient prognosis in surgically resected small cell lung cancer.
    Carey FA; Gray E; O'Mahony M; Craig SR; Salto-Tellez M; Lamb D
    Anal Cell Pathol; 1996 Dec; 12(3):137-43. PubMed ID: 9025990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.